2022 Partners:

Curi-Bio-Logo_full-color-for-light-bgs_no-space (002)

Curi Bio 

Innovation Partner

Curi Bio’s preclinical discovery platform combines human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic screening data to accelerate the discovery, safety testing, and efficacy testing of new drugs. These products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models. By offering this highly predictive platform, Curi is closing the gap between
preclinical data and human-relevant results—accelerating the development of safer, more effective medicines.